Aspirin for preventing the recurrence of venous thromboembolism

by medstaff on June 19, 2012

 (NEJM, May 17) and the accompanying editorial Warfarin in heart failure concludes “the  results of the WARCEF trial are consistent with those of three previous smaller randomized, controlled trials in showing that warfarin anticoagulant therapy, as compared with aspirin, is not associated with a reduction in mortality among patients with heart failure. The WARCEF trial provides clear evidence that anticoagulant therapy prevents stroke, probably embolic stroke, in patients with heart failure who have severe systolic dysfunction, but the rates of stroke are too low to justify the routine clinical use of warfarin in most patients with heart failure, in light of the increase in the risk of bleeding.